|
|
Article: FOSAMAX Increased Bone Mineral Density Twice As Much as Evista.
- Article from:
- Business Wire
- Article date:
- September 22, 2003
CopyrightCOPYRIGHT 2003 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health & Pharmaceutical Writers
MINNEAPOLIS--(BUSINESS WIRE)--Sept. 22, 2003
Merck & Co., Inc. (NYSE:MRK)
FOSAMAX and Evista Demonstrated Similar Upper GI Safety and Overall
Tolerability Profiles in Two Head-to-Head Studies Presented at ASBMR
In one-year head-to-head trials comparing FOSAMAX(R)(alendronate sodium) once-weekly, the most prescribed medicine(1) for osteoporosis treatment, to Evista, FOSAMAX 70 mg provided significantly greater increases in bone mineral density (BMD) at one-year at the lumbar spine and total hip compared to Evista (raloxifene) 60 mg once-daily. Findings from these two studies, one ...